门冬氨酸鸟氨酸治疗慢重肝合并肝性脑病疗效观察

目的评价门冬氨酸鸟氨酸治疗慢性重型肝炎合并肝性脑病的临床疗效。方法将97例合并肝性脑病的慢性重型肝炎患者随机分为两组，两组均接受综合治疗，治疗组加用门冬氨酸鸟氨酸治疗，并评价患者治疗前后肝性脑病分级，检测治疗前后的肝功能、凝血酶原活动度和血氨。结果门冬氨酸鸟氨酸治疗肝性脑病有效率（72．3％）明显优于对照组（44．0％），P〈0．005；治疗组肝功能、凝血酶原活动度（PTA）和血氨均优于对照组，P〈0．05；且无不良反应。结论门冬氨酸鸟氨酸可以有效治疗慢重肝合并肝性脑病。

Clinical efficacy of L-ornithine-L-asparatate in the management of chronic severe hepatitis complicated with hepatic encephalopathy

Objective To evaluate clinical efficacy of L-ornithine-L-asparatate in the management of chronic severe hepatitis complicated by hepatic encephalopathy （HE）. Methods Total 97 patients with chronic severe hepatitis complicated by HE were randomly divided into therapy group and control group, patients in the both two group were treated with routine comprehensive therapy, and those in the therapy group received additional management of L-ornithine-L-asparatate. The West Haven criteria of altered mental state in HE, liver function tests, prosthrombin activity and ammonia were tested in all patients at the onset and end of treatment. Results The effective rate of L-omithine-L-asparatate in the management of HE （72.3%）was higher than that of the control group （44.0%）, P〈0.005. The improvement of liver function, prosthrombin activity and ammonia in the therapy group were obviously better than that in the control group, P〈0.005. And no significant side effect was observed in the L-ornithine-L-asparatate treatment. Conclusions L-omithine- L-asparatate is effective for chronic severe hepatitis complicated with HE.